22 May 2013
Keywords: watson, oxybutynin, patch, gets, eu, ok, european
Article | 28 June 2004
The European Commission has approved USA-based Watson Pharmaceutical's oxybutynin transdermal patch for the symptomatic treatment of urge
incontinence and/or ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
28 June 2004
21 May 2013
© 2013 thepharmaletter.com